Agenus (AGEN)
3.23
-0.16 (4.72%)
Upcoming Events
Latest Headlines
Agenus Announces Virtual 2026 Annual Shareholders Meeting
June 2, 2026 4:30 PM - BizWire
Form 4 AGENUS INC For: May 29 Filed by: ARMEN GARO H
June 2, 2026 6:09 AM - SEC Filing
Agenus reports AI analysis shows improved response rates for cancer treatment
May 21, 2026 5:00 PM - StreetInsider
Agenus reports melanoma trial data for drug combination BOT+BAL
May 21, 2026 5:00 PM - StreetInsider
Agenus Presents Phase 2 BOT+BAL Melanoma Data Showing Durable Responses and Meaningful Survival in Advanced Checkpoint-Refractory Melanoma at ASCO 2026
May 21, 2026 5:00 PM - BizWire
Agenus and Noetik Present ASCO 2026 Data Linking AI Analysis of Routine Pretreatment Tumor Pathology Images to Response and Survival with BOT+BAL in MSS Metastatic CRC
May 21, 2026 5:00 PM - BizWire
Form 4 AGENUS INC For: May 15 Filed by: ARMEN GARO H
May 19, 2026 5:01 PM - SEC Filing
Form 8-K AGENUS INC For: May 12
May 15, 2026 4:13 PM - SEC Filing
Agenus publishes phase 1b data for liver cancer drug combination
May 15, 2026 4:11 PM - StreetInsider
Agenus Announces Publication of Phase 1b Botensilimab and Balstilimab Data in Post-Immunotherapy Hepatocellular Carcinoma in Liver Cancer
May 15, 2026 4:11 PM - BizWire
Form DEFA14A AGENUS INC
May 13, 2026 2:59 PM - SEC Filing
Form 10-Q AGENUS INC For: Mar 31
May 11, 2026 5:05 PM - SEC Filing
Form 8-K AGENUS INC For: May 11
May 11, 2026 8:52 AM - SEC Filing
Agenus reports $4.6 million in pre-commercial revenue for Q1 2026
May 11, 2026 8:45 AM - StreetInsider
Agenus Reports First Quarter 2026 Financial Results and Highlights BOT+BAL Execution Across Global Access and Phase 3 Development
May 11, 2026 8:45 AM - BizWire
Form 4 AGENUS INC For: May 01 Filed by: ARMEN GARO H
May 5, 2026 5:49 PM - SEC Filing
Agenus to Provide First Quarter 2026 Financial Report and Corporate Update
May 4, 2026 4:30 PM - BizWire
Form ARS AGENUS INC For: Dec 31
April 30, 2026 4:37 PM - SEC Filing
Form DEF 14A AGENUS INC For: Apr 30
April 30, 2026 4:35 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: O'Day Steven J
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Buell Jennifer
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Wright Timothy
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Charette Austin
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: HARRISON THOMAS L
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Hirsch Susan B
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: Corvese Brian
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 24 Filed by: ARMEN GARO H
April 28, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 17 Filed by: ARMEN GARO H
April 21, 2026 4:15 PM - SEC Filing
Agenus to present melanoma data at ASCO 2026
April 21, 2026 10:00 AM - StreetInsider
Agenus to Present First Phase 2 Botensilimab Data in Advanced Cutaneous Melanoma at ASCO 2026
April 21, 2026 10:00 AM - BizWire
Agenus Names BAP Pharma as Exclusive Global Partner for BOT+BAL Access Programs
April 21, 2026 8:00 AM - BizWire
Form PRE 14A AGENUS INC For: Apr 20
April 20, 2026 5:22 PM - SEC Filing
Agenus reports mixed results from gastroesophageal cancer trial
April 17, 2026 4:45 PM - StreetInsider
Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer
April 17, 2026 4:43 PM - BizWire
Form 4 AGENUS INC For: Apr 01 Filed by: HARRISON THOMAS L
April 13, 2026 4:15 PM - SEC Filing
Form 4 AGENUS INC For: Apr 03 Filed by: ARMEN GARO H
April 6, 2026 4:15 PM - SEC Filing
Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026
April 3, 2026 7:30 AM - BizWire
Form 4 AGENUS INC For: Apr 01 Filed by: Wright Timothy
April 2, 2026 4:31 PM - SEC Filing
Agenus enrolls first patient in phase 3 colorectal cancer trial
April 1, 2026 7:30 AM - StreetInsider
Agenus begins phase 3 trial for colorectal cancer immunotherapy
April 1, 2026 7:30 AM - StreetInsider
Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer
April 1, 2026 7:30 AM - BizWire
Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access
March 26, 2026 4:52 PM - BizWire
Form SCHEDULE 13G/A AGENUS INC Filed by: VANGUARD GROUP INC
March 26, 2026 3:12 PM - SEC Filing
Form 8-K AGENUS INC For: Mar 24
March 26, 2026 8:25 AM - SEC Filing
Form 4 AGENUS INC For: Mar 20 Filed by: ARMEN GARO H
March 24, 2026 4:15 PM - SEC Filing
Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer
March 17, 2026 4:40 PM - BizWire
B.Riley on Agenus Inc. (AGEN) Amid 8pct Gain: 'The stock remains deeply undervalued at a near-zero EV'
March 17, 2026 10:33 AM - StreetInsider
Form 10-K AGENUS INC For: Dec 31
March 16, 2026 5:20 PM - SEC Filing
Form 8-K AGENUS INC For: Mar 16
March 16, 2026 8:15 AM - SEC Filing
Agenus advances cancer drug combo to phase 3, reports early revenue
March 16, 2026 7:30 AM - StreetInsider
Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized
March 16, 2026 7:30 AM - BizWire
Agenus receives first $20M payment from Zydus collaboration
March 10, 2026 7:30 AM - StreetInsider
Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs
March 10, 2026 7:30 AM - BizWire
Form 4 AGENUS INC For: Mar 06 Filed by: ARMEN GARO H
March 9, 2026 4:16 PM - SEC Filing
Full Article List
